Viridian Therapeutics, Inc./DE Increase (Decrease) in Accounts Payable and Accrued Liabilities
Viridian Therapeutics, Inc./DE (VRDN) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.03 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2017-03-24
- Viridian Therapeutics, Inc./DE increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2016-12-31 was $1.67M, a 411.66% increase year-over-year.
- Viridian Therapeutics, Inc./DE increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2016-09-30 was $249.00K, a 236.49% increase year-over-year.
- Viridian Therapeutics, Inc./DE increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2016-06-30 was $147.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2016-03-31 was -$36.00K, a 108.98% decline year-over-year.
- Viridian Therapeutics, Inc./DE increase (decrease) in accounts payable and accrued liabilities for fiscal 2016 was $2.03M, a 220.38% increase from fiscal 2015.
- Viridian Therapeutics, Inc./DE increase (decrease) in accounts payable and accrued liabilities for fiscal 2015 was $633.00K, a 65.27% increase from fiscal 2014.
- Viridian Therapeutics, Inc./DE increase (decrease) in accounts payable and accrued liabilities for fiscal 2014 was $383.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in accounts payable and accrued liabilities for fiscal 2013 was -$280.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2016-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $1.92M derived: sum of 2 quarters · filed 2017-03-24 | $2.06M derived: sum of 3 quarters · filed 2017-03-24 | $2.03M 10-K · filed 2017-03-24 | ||
| 2016-09-30 | $249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $396.00K derived: sum of 2 quarters · filed 2016-10-26 | $360.00K 10-Q · filed 2016-10-26 | $686.00K derived: sum of 4 quarters · filed 2017-03-24 | ||
| 2016-06-30 | $147.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $111.00K 10-Q · filed 2016-08-15 | $437.00K derived: sum of 3 quarters · filed 2017-03-24 | $511.00K derived: sum of 4 quarters · filed 2017-03-24 | ||
| 2016-03-31 | -$36.00K 10-Q · filed 2016-05-16 | $290.00K derived: sum of 2 quarters · filed 2017-03-24 | $364.00K derived: sum of 3 quarters · filed 2017-03-24 | $196.00K derived: sum of 4 quarters · filed 2017-03-24 | ||
| 2015-12-31 | $326.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | $400.00K derived: sum of 2 quarters · filed 2017-03-24 | $232.00K derived: sum of 3 quarters · filed 2017-03-24 | $633.00K 10-K · filed 2017-03-24 | ||
| 2015-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | -$94.00K derived: sum of 2 quarters · filed 2016-10-26 | $307.00K 10-Q · filed 2016-10-26 | $286.00K derived: sum of 4 quarters · filed 2016-10-26 | ||
| 2015-06-30 | -$168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $233.00K 10-Q · filed 2016-08-15 | $212.00K derived: sum of 3 quarters · filed 2016-08-15 | $538.00K derived: sum of 4 quarters · filed 2016-08-15 | ||
| 2015-03-31 | $401.00K 10-Q · filed 2016-05-16 | $380.00K derived: sum of 2 quarters · filed 2016-05-16 | $706.00K derived: sum of 3 quarters · filed 2016-05-16 | $775.00K derived: sum of 4 quarters · filed 2016-05-16 | ||
| 2014-12-31 | -$21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | $305.00K derived: sum of 2 quarters · filed 2016-03-21 | $374.00K derived: sum of 3 quarters · filed 2016-03-21 | $383.00K 10-K · filed 2016-03-21 | ||
| 2014-09-30 | $326.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $395.00K derived: sum of 2 quarters · filed 2015-11-13 | $404.00K 10-Q · filed 2015-11-13 | $404.36K 10-Q · filed 2014-11-14 | $394.25K derived: sum of 4 quarters · filed 2015-11-13 | |
| 2014-06-30 | $69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $78.00K 10-Q · filed 2015-08-14 | $77.97K 10-Q · filed 2014-08-14 | $68.25K derived: sum of 3 quarters · filed 2015-08-14 | $96.67K derived: sum of 4 quarters · filed 2015-08-14 | |
| 2014-03-31 | $9.00K 10-Q · filed 2015-05-15 | -$751.00 derived: sum of 2 quarters · filed 2015-05-15 | $27.67K derived: sum of 3 quarters · filed 2015-05-15 | |||
| 2013-12-31 | -$9.75K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $18.67K derived: sum of 2 quarters · filed 2015-03-27 | -$280.00K 10-K · filed 2015-03-27 | |||
| 2013-09-30 | $28.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-14 | -$270.25K 10-Q · filed 2014-11-14 | ||||
| 2013-06-30 | -$298.67K 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |